Chiasma Inc. (CHMA) and Its Competitors Financial Results Comparison

We are contrasting Chiasma Inc. (NASDAQ:CHMA) and its rivals on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. They are Biotechnology companies, competing one another.

Insider & Institutional Ownership

76.5% of Chiasma Inc.’s shares are owned by institutional investors. Comparatively, 53.20% of all Biotechnology’s companies shares are owned by institutional investors. On other hand Chiasma Inc. has 6.21% of its shares owned by company insiders and an average of 8.45% insiders ownership for its competitors.


On first table we have Chiasma Inc. and its competitors’ return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Chiasma Inc. 581,558,935.36% -88.00% -58.40%
Industry Average 812.10% 105.95% 28.39%

Valuation & Earnings

The following data compares Chiasma Inc. and its competitors’ valuation, net profit and top-line revenue.

Net Income Gross Revenue Price/Earnings Ratio
Chiasma Inc. 30.59M 5 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Ratings

Table 3 shows summary of recent ratings for Chiasma Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Chiasma Inc. 0 0 1 3.00
Industry Average 1.10 1.78 2.38 2.81

$11 is the average price target of Chiasma Inc., with a potential upside of 107.94%. The potential upside of the peers is 168.19%. By having stronger average rating and higher possible upside, Chiasma Inc. make equities research analysts believe that the company is more favorable than its rivals.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Chiasma Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Chiasma Inc. -15.54% -31.12% -5.51% 58.67% 292.14% 76.53%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year Chiasma Inc. was more bullish than its peers.


Chiasma Inc. has a Current Ratio of 1.9 and a Quick Ratio of 1.9. Competitively, Chiasma Inc.’s peers Current Ratio is 7.07 and has 6.86 Quick Ratio. Chiasma Inc.’s rivals have better ability to pay short and long-term obligations than Chiasma Inc.

Volatility and Risk

Chiasma Inc. is 12.00% more volatile than Standard & Poor’s 500 because the stock has a beta of 1.12. Competitively, Chiasma Inc.’s rivals are 76.75% more volatile than Standard & Poor’s 500, because of the 1.77 beta.


Chiasma Inc. does not pay a dividend.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.